Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version 5, following a memo issued by the Sponsor, participants receiving treatment in the atezolizumab plus bevacizumab plus tiragolumab arm are recommended to discontinue tiragolumab treatment unless the investigator decides the benefit outweighs the risk. Participants receiving treatment in atezolizumab plus bevacizumab plus placebo arm must discontinue placebo treatment. Participants may continue receiving active treatment(s) per protocol until loss of clinical benefit or unacceptable toxicity, whichever occurs first.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- OTHER Placebo
- DRUG Tiragolumab
Study Locations (20)
California
- UCSF Fresno at Community Cancer Institute — Clovis
- City of Hope Cancer Center — Duarte
- University of California San Diego Moores Cancer Center — La Jolla
- University of Southern California — Los Angeles
- Stanford Cancer Center — Palo Alto
- Va Palo Alto Health Care System — Palo Alto
- UCLA Cancer Center — Santa Monica
Florida
- Florida Cancer Specialists - Fort Myers (Broadway) — Fort Myers
- Miami VA Healthcare System — Miami
- Florida Cancer Specialist, North Region — St. Petersburg
Michigan
- Henry Ford Health System — Detroit
- Cancer & Hematology Centers of Western Michigan — Grand Rapids
Arkansas
- Genesis Cancer Center — Hot Springs
Connecticut
- Hartford Healthcare Cancer Institute at Hartford Hospital — Hartford
District of Columbia
- MedStar Washington Hosp Center — Washington D.C.
Illinois
- University of Illinois — Chicago
Kentucky
- Norton Cancer Institute - Audubon — Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 687 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05904886
The ClinicalTrials.gov registry entry for NCT05904886 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 687 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 758 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 4 interventions — of which Bevacizumab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05904886 reports 20 study locations spanning 11 distinct geographic areas — top geographies include California, Florida, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05904886 about?
NCT05904886 is a clinical study titled "A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)". The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version ...
What is the current status of trial NCT05904886?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 687 participants. The study started on 2023-09-14. Estimated completion is 2026-09-01.
What conditions does trial NCT05904886 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05904886?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Placebo (OTHER), Tiragolumab (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05904886?
This trial is sponsored by Hoffmann-La Roche, which has 758 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05904886 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.